Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shire has signed a co-promotion agreement with GlaxoSmithKline for Vyvanse capsules CII with the aim of improving recognition and treatment of attention deficit hyperactivity disorder in adults.
Subscribe to our email newsletter
The three-year agreement covers the US and will more than double the reach and frequency of the current sales effort for Vyvanse by adding over 600 sales representatives from GlaxoSmithKline (GSK) who call on specialists and primary care physicians, said Shire.
Shire added that it currently has nearly 600 representatives promoting Vyvanse, primarily to pediatricians and psychiatrists.
The GSK sales force is expected to begin promoting Vyvanse to physicians in May 2009. The agreement is based on profit-sharing above an agreed-upon baseline figure. Vyvanse is currently available in six dosage strengths of 20mg, 30mg, 40mg, 50mg, 60mg and 70mg.
Deirdre Connelly, president of GlaxoSmithKline North American Pharmaceuticals, said: “GSK has been active in discovering and developing medicines to treat psychiatric disorders for decades, and neuroscience is one of the company’s key therapeutic categories. Our professional sales representatives are well positioned to provide physicians with information on the treatment of adult attention deficit hyperactivity disorder (ADHD) with Vyvanse and we look forward to helping meet the needs of adult patients with ADHD.”